Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Montecito Bank & Trust

Montecito Bank & Trust lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 89.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,114 shares of the biopharmaceutical company’s stock after acquiring an additional 526 shares during the period. Montecito Bank & Trust’s holdings in Regeneron Pharmaceuticals were worth $1,171,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Sachetta LLC boosted its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at $26,000. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $28,000. Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $33,000. Finally, Family Firm Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. TD Cowen upped their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada lowered their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,092.62.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $816.65 on Thursday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $90.03 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 3.17 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a twelve month low of $783.57 and a twelve month high of $1,211.20. The firm has a 50-day moving average of $1,035.92 and a two-hundred day moving average of $1,038.36.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.